

Policy Name	Clinical Policy – Experimental and Investigational Services
Policy Number	1323.00
Department	Clinical Product & Development
Subcategory	Medical Management
Original Approval Date	04/25/2018
Current MPC/CCO Approval Date	04/03/2024
Current Effective Date	07/01/2024

Company Entities Supported (Select All that Apply)

☒ Superior Vision Benefit Management
☒ Superior Vision Services
☒ Superior Vision of New Jersey, Inc.
☒ Block Vision of Texas, Inc. d/b/a Superior Vision of Texas
☒ Davis Vision
 (Collectively referred to as 'Versant Health' or 'the Company')

Acronyms and Definitions

CPT® Category III Codes	Category III codes are temporary codes created to track safety and usage data of new, emerging unproven therapies and tests. All Category III Codes have a sunset date, at which time the CPT® editorial panel may convert it to a Category I code or delete the code if widespread use of the service has not materialized, or they may extend the code as Category III for several more years. See "Sources" for CPT® III criteria.
Category III procedure/T Codes	Temporary codes to track utilization of emerging technologies, services, or procedures. Category III/T code designation does not establish safety, efficacy, medical necessity nor improved health outcomes.
DHHS	U.S. Department of Health and Human Services
Experimental	Therapies, services, procedures, surgeries, or diagnostics where safety and efficacy has not been established.
FDA	U.S. Food and Drug administration which approves pharmaceuticals and devices for the initial investigational use.
FDA Categories	Category A. - Safety and efficacy has not been established. Category B - Safety and efficacy have been established but criteria for medical necessity and evidence of improved health outcomes have not been established

Investigational	Therapies or diagnostics that are not recognized as standard medical care for the condition, disease, illness, or injury being treated and where safety and efficacy have not been established
Technology Assessment Reports	Formal documents resulting from the industry and scientific review of new or not widely adopted therapies and diagnostics.

PURPOSE

To define the medical necessity criteria to support the indication(s) for experimental and investigational procedures, medications, diagnostic tools, and devices, plus AMA designated CPT® Level 3 codes.

POLICY

A. BACKGROUND

The Versant Health medical management department regularly reviews experimental, investigational, and unproven treatments that include CPT® Code III procedures, plus FDA approved drugs and devices that are not yet in widespread use, CMS released new technologies, and the use of FDA approved drugs or procedures for an unapproved (off label) use. These reviews may result in a formal technology assessment report that is further reviewed by governance committees.

1. The new technology assessment reports establish either:
 - a. That the new or existing technology is considered experimental and/or investigational, thus, not adopted into the program services, or
 - b. That the new or existing technology will be included as a therapeutic service.
2. Technologies which are not adopted as medically necessary treatments are retained on the new technology/CPT® III code tracker for ongoing tracking and future review.
3. The assessment of experimental and investigational services for program inclusion includes research from the following sources:
 - a. Medicare/CMS Technology Assessments
 - b. Client health plan criteria for alignment with specific CPT® III code, drug, diagnostic tool, or device.
 - c. Industry coverage and commentary of the specified technology.
 - d. Evidence based criteria from scientific research published in peer reviewed journals.

B. Medically Necessary

The assessment of experimental or investigational service requests includes the information stated above plus a review of the member's individualized medical necessity which includes the member's regional variation and access to care, as follows:

1. General acceptance of the treatment by the medical community as safe and effective in treatment of the condition in the setting for which the use is proposed; and,
2. Medically necessary to provide the diagnosis, direct care and treatment of the patient's condition, illness, disease or injury; and,
3. Is in accordance with professional, evidence based medical and recognized standards of good medical practice and care; and,
4. Provided at a level of duration and/or dosage that is medically appropriate and,
5. Not furnished primarily for the convenience of the patient, the physician, or supplier; and,
6. Treatment consensus is obtained with the member's health plan, as contractually required.
7. Versant Health will provide medical review of excluded experimental and investigational treatments for expanded use, i.e. compassionate use, when no comparable or satisfactory alternative therapy options are available. ^{1 2}

C. Not Medically Necessary

1. Versant Health does not consider any experimental device, procedure, drug, therapy, treatment, biologic product or instrument to be medically necessary.
2. In rare circumstances investigational devices, procedures, or drugs may be considered medically appropriate. No investigational devices, drugs, or procedures are included in Versant Health programs except as documented in the formal clinical policies.
3. Versant Health considers any device, procedure, protocol, drug, therapy, treatment, biologic product or instrument to be experimental and/or investigational if it meets any of these criteria:
 - a. It has not received final approval by the FDA, any interim approvals or instrument, drug or device investigative exemptions, Category A or Category B classifications are insufficient.
 - b. Has not been approved by the controlling governmental regulatory authority.
 - c. Not proven to be safe and effective based upon authoritative peer reviewed literature.
 - d. Performed under a protocol that requires or should require oversight by an institutional review board (IRB)
 - e. Does not demonstrate improved health outcomes.

¹ FDA, Expanded Access. 2024

² NCQA 2023 Health Plan Standards and Guidelines

- f. If a comparable outcome can be achieved by a device, procedure, protocol, drug, therapy, treatment, biologic product or instrument that is not experimental and/or investigational and is already in common and accepted use in medical practice.
- g. Furnished at a level, duration or frequency not supported by peer-reviewed medical literature.
- h. Not furnished in a setting (such as inpatient care at a hospital or SNF, outpatient care through a hospital or physician's office or home care) appropriate to the patient's medical needs and condition.
- i. Referred to as experimental, investigational, clinical trial, research project or similar language by other institutions studying the same or similar device, procedure, protocol, drug, therapy, treatment, biologic product or instrument.
- j. It is not itself experimental and/or investigational but is being used in an assessment of a service, device, procedure, protocol, drug, therapy, treatment, biologic product or instrument that does meet the criteria of experimental and/or investigational.

D. Documentation for Experimental or Investigational Services Request

Medical necessity must be supported by adequate and complete documentation in the patient's medical record that describes the procedure and the medical rationale as in requirements above. For any retrospective review, a full operative report and/or the clinical care plan is needed.

All medical record items must be available upon request to initiate or sustain previous payments. Every page of the record must be legible and include appropriate patient identification information (e.g., complete name, date(s) of service). Services provided or ordered must be authenticated by the physician, in a handwritten or electronic signature. Stamped signatures are not acceptable. For retrospective reviews, the full operative report and/or the clinical care plan is required.

DISCLAIMER and COPYRIGHTS

This clinical policy is provided for information purposes only and does not constitute medical advice. Versant Health, Inc., and its affiliates (the "Company") do not provide health care services and cannot guarantee any results or outcomes. Treating doctors are solely responsible for determining what services or treatments to provide to their patients. Patients (members) should always consult their doctor before making any decisions about medical care.

Subject to applicable law, compliance with this clinical policy is not a guarantee of coverage or payment. Coverage is based on the terms of an individual's particular benefit plan document, which may not cover the service(s) or procedure(s) addressed in this clinical policy. The terms of the individual's specific benefit plan are always determinative.

Every effort has been made to ensure that the information in this clinical policy is accurate and complete, however the Company does not guarantee that there are no errors in this

policy or that the display of this file on a website is without error. The company and its employees are not liable for any errors, omissions, or other inaccuracies in the information, product, or processes disclosed herein. Neither the company nor the employees represent that the use of such information, products, or processes will not infringe on privately owned rights. In no event shall the Company be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information, product, or process.

COMPANY'S COPYRIGHT STATEMENT Except for any copyrights described below, this clinical policy is confidential and proprietary, and no part of this clinical policy may be reproduced, distributed or used without Versant Health, or its applicable affiliates, express prior written approval.

AMA COPYRIGHT STATEMENT CPT® is the 2002-2024 copyright of the American Medical Association. All Rights Reserved. CPT™ is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT®, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

RELATED POLICIES AND PROCEDURES	
1324	Category III Services (retired 2020)

DOCUMENT HISTORY		
<i>Approval Date</i>	<i>Revision</i>	<i>Effective Date</i>
04/25/2018	Initial policy	04/25/2018
07/25/2019	Annual review; no criteria changes.	07/25/2019
06/03/2020	Combine with policy 1324.00 Category III codes.	07/01/2020
04/07/2021	Annual review; no criteria changes.	07/01/2021
04/06/2022	Annual review; no criteria changes.	05/01/2022
04/12/2023	Separate experimental and investigational procedures into two categories; add description of how investigational treatments may be included in program.	07/01/2023
04/03/2024	Added compassionate use exception for medical review.	07/01/2024

REFERENCES AND SOURCES

1. Andrade EL, Bento AF, Cavalli J, et al. non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety, and dose translation to clinical studies. *Braz J Med Biol Res.* 2016; 49(12): e5646. Published 2016 Dec.
2. Beebe DB, Rosenfeld AB, Collins N. An approach to decisions about coverage of investigational treatments. *HMO Pract.* 1997;11(2):65-67.
3. Eddy DM. Investigational treatments. How strict should we be? *JAMA (Journal of the American Medical Association) (Journal of the American Medical Association).* 1997 6;278(3):179-185.
4. Holbein ME, Berglund JP. Understanding Food and Drug Administration regulatory requirements for an investigational device exemption for sponsor-investigators. *J Investig Med.* 2012; 60(7):987–994.
5. Nair AB, Shah J, Jacob S, et.al. Experimental design, formulation and in vivo evaluation of a novel topical in situ gel system to treat ocular infections. *PLoS One.* 2021 Mar 19;16(3):e0248857. doi: 10.1371/journal.pone.0248857. PMID: 33739996; PMCID: PMC7978349.
6. Priester R, Vawter DE, Gervais KG. Investigational treatments: Process, payment, and priorities. *JAMA.* 1997;278(17):1403-1404.
7. Speers MA. Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program. *Pharmaceut Med.* 2019 Apr;33(2):89-98. doi: 10.1007/s40290-019-00274-3. Erratum in: *Pharmaceut Med.* 2020 Aug;34(4):295. PMID: 31933253.
8. Televi A, Bellera CL. Challenges and opportunities with drug repurposing. *Expert Opinion on Drug Discovery.* Vol. 15, 2020.
<https://doi.org/10.1080/17460441.2020.1704729> .
9. Tolentino MJ, Tolentino AJ. Investigational drugs in clinical trials for macular degeneration. *Expert Opin Investig Drugs.* 2022 Oct;31(10):1067-1085. doi: 10.1080/13543784.2022.2113375. Epub 2022 Sep 20. PMID: 35962560.

SOURCES

1. AMA CPT® Category III Long Descriptor document. July 1, 2023. Issued and updated biannually. <https://www.ama-assn.org/practice-management/cpt/category-iii-codes>. Accessed 2/2024.
2. CMS: Factors CMS Considers in Commissioning External Technology Assessments. April 11, 2006. <https://www.cms.gov/medicare-coverage-database/view/medicare-coverage-document.aspx?MCDId=7>. Accessed 2/2024.
3. Definition of experimental procedures: a committee opinion. *Fertil Steril.* 2013; [https://www.fertstert.org/article/S0015-0282\(12\)02545-9/fulltext](https://www.fertstert.org/article/S0015-0282(12)02545-9/fulltext). Accessed 2/2024. Retiree Guide. What does Medicare not cover in 2023.
<https://www.retireguide.com/medicare/original-medicare/not->

[covered/#:~:text=Generally%2C%20Original%20Medicare%20does%20not,lenses%20aren't%20generally%20covered](#). Accessed 2/2024.

4. FDA Expanded Access. <https://www.fda.gov/news-events/public-health-focus/expanded-access>. Accessed 2/2024.
5. Medical devices; investigational device exemptions--FDA. <https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/investigational-device-exemption-ide>. Accessed 2/2024.
6. NCQA 2023 Utilization Management Standards. Requirements for UM processes for experimental/investigational and program to review new technologies. 2023 Health Plan Standards and Guidelines. Accessed 3/2024.